Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ambipar Emergency ResponseAMBIQ · Entity 8768 | Director | March 18, 2026 | March 18, 2026 |
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 13, 2026 |
| BurgerFi International, Inc.OPES · Entity 87763 | Director · Chief Executive Officer | October 28, 2019 | November 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ambipar Emergency Response
Report date March 18, 2026 · Filed March 18, 2026
This filing explicitly reported no securities owned.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
BurgerFi International, Inc.
Report date October 28, 2019 · Filed November 01, 2019
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TERRAFORM GLOBAL, INC.
Report date December 28, 2017 · Filed January 03, 2018
Section 16 reporting ended · disclosed 2018-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Class A common stock)SEC Table II · derivative / convertible security | Direct | 12,081 |
Reported balance
After 2017-12-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-12-28 · Disposition to issuer · Disposed 55,419 · Balance 12,081 F1: On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. ("Merger Sub"), Merger Sub merged with and into TerraForm Global, Inc. (the "Merger"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings. |
| Restricted Stock Units (Class A common stock)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-12-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-12-28 · Other · Disposed 12,081 · Balance 0 F2: This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. ("Merger Sub"), Merger Sub merged with and into TerraForm Global, Inc. (the "Merger"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings.
F2: This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 00:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-26-002973 · tm262917-1_4seq1.xml · derivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-105760 · tm2530101-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 01:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-105760 · tm2530101-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-095739 · tm2527731-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,694 Underlying: Common Stock · 1,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-095739 · tm2527731-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 31, 2025 Filed Sep 2, 2025 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-086528 · tm2524989-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,387 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| August 31, 2025 Filed Sep 2, 2025 23:00 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-086528 · tm2524989-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,930 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 20:15 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-072701 · tm2521524-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,080 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| July 31, 2025 Filed Jul 31, 2025 20:15 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-072701 · tm2521524-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 20:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-064148 · tm2519495-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,773 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 20:30 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-064148 · tm2519495-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 23:10 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-055610 · tm2516926-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,466 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 23:10 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-055610 · tm2516926-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| April 30, 2025 Filed May 1, 2025 23:23 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-043628 · tm2513761-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,159 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| April 30, 2025 Filed May 1, 2025 23:23 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-043628 · tm2513761-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-030679 · tm2511097-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,852 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 22:02 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-030679 · tm2511097-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 02:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 1,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-020519 · tm258264-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,545 Underlying: Common Stock · 1,693 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last day of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last day of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 02:21 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 1,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-020519 · tm258264-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:28 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 27,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-009204 · tm255496-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,810 Underlying: Common Stock · 27,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:28 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 27,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-009204 · tm255496-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 27,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000782 · tm251731-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,899 Underlying: Common Stock · 27,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 27,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000782 · tm251731-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 21:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 27,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-125073 · tm2430075-1_4seq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 30, 2024 Filed Dec 4, 2024 21:05 UTC Amendment | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionRestricted Stock Units · Derivative | 27,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125506 · tm2430194-1_4aseq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 297,988 Underlying: Common Stock · 27,089 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| November 30, 2024 Filed Dec 4, 2024 21:05 UTC Amendment | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | Exercise / conversionCommon Stock | 27,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-125506 · tm2430194-1_4aseq1.xml · nonDerivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:06 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 325,077 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-122570 · tm2429407-2_4seq1.xml · derivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,077 Underlying: Common Stock · 325,077 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| November 21, 2024 Filed Dec 3, 2024 21:05 UTC | BioXcel Therapeutics, Inc. BTAI · Entity 8380 | GrantRestricted Stock Units · Derivative | 297,988 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125073 · tm2430075-1_4seq1.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 297,998 Underlying: Common Stock · 297,988 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. F2 · derivative.expiration_date: On November 21, 2024, the Reporting Person was granted 325,077 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period. Read SEC document |
| December 28, 2017 Filed Jan 3, 2018 02:26 UTC | TERRAFORM GLOBAL, INC. GLBL · Entity 170596 | OtherRestricted Stock Units (Class A common stock) · Derivative | 12,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001620702-18-000012 · wf-form4_151494635471908.xml · derivative · entry 2 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,081 shares Expires not disclosed F2 · derivative.exercise_price: This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger. F2 · kind: This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger. F2 · derivative.exercise_date: This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger. F2 · derivative.expiration_date: This number represents restricted stock units that were forfeited in accordance with the applicable grant agreement, which provided for pro-rated vesting of the restricted stock units based on the effective time of the Merger. Read SEC document |
| December 28, 2017 Filed Jan 3, 2018 02:26 UTC | TERRAFORM GLOBAL, INC. GLBL · Entity 170596 | Disposition to issuerRestricted Stock Units (Class A common stock) · Derivative | 55,419 | $5.10 | $282,636.90 |
DisclosureSEC source: 0001620702-18-000012 · wf-form4_151494635471908.xml · derivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,081 Underlying: Class A Common Stock · 55,419 shares Expires not disclosed F1 · derivative.exercise_price: On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. ("Merger Sub"), Merger Sub merged with and into TerraForm Global, Inc. (the "Merger"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings. F1 · derivative.exercise_date: On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. ("Merger Sub"), Merger Sub merged with and into TerraForm Global, Inc. (the "Merger"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings. F1 · derivative.expiration_date: On December 28, 2017, pursuant to the Agreement and Plan of Merger, dated as of March 6, 2017, by and among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. ("Merger Sub"), Merger Sub merged with and into TerraForm Global, Inc. (the "Merger"), with TerraForm Global, Inc. continuing as the surviving corporation in the Merger and a wholly-owned subsidiary of Orion US Holdings 1 L.P. At the effective time of the Merger, for each restricted stock unit, restricted stock award and share of Class A common stock held by the filer, the filer received $5.10 per share, subject to relevant tax withholdings. Read SEC document |
| August 04, 2017 Filed Aug 8, 2017 23:01 UTC | TERRAFORM GLOBAL, INC. GLBL · Entity 170596 | GrantRestricted Stock Units (Class A common stock) · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001620702-17-000079 · wf-form4_150223326388744.xml · derivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Class A Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: On August 4, 2017, 30,000 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock. F2 · derivative.exercise_price: The 30,000 restricted stock units will vest in full on June 29, 2018. In the event that prior to June 29, 2018: (i) the Participant resigns with the consent of the Board, (ii) the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (iii) a Change in Control occurs due to a merger of the Company pursuant to the Agreement and Plan of Merger dated as of March 6, 2017 among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (the "Brookfield Merger Agreement") a portion of the restricted stock units equal to Prorated Vesting Percentage (as defined below) shall become fully vested. F3 · derivative.exercise_price: The "Prorated Vesting Percentage" means the percentage calculated by dividing (i) the number of days between May 25, 2017 and, as applicable, (x) the date the Participant resigns with the consent of the Board, (y) the date the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (z) the date of the Effective Time (as defined in the Brookfield Merger Agreement), by (ii) 365; provided, that the Prorated Vesting Percentage shall not exceed 100%. F1 · derivative.exercise_date: On August 4, 2017, 30,000 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock. F2 · derivative.exercise_date: The 30,000 restricted stock units will vest in full on June 29, 2018. In the event that prior to June 29, 2018: (i) the Participant resigns with the consent of the Board, (ii) the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (iii) a Change in Control occurs due to a merger of the Company pursuant to the Agreement and Plan of Merger dated as of March 6, 2017 among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (the "Brookfield Merger Agreement") a portion of the restricted stock units equal to Prorated Vesting Percentage (as defined below) shall become fully vested. F3 · derivative.exercise_date: The "Prorated Vesting Percentage" means the percentage calculated by dividing (i) the number of days between May 25, 2017 and, as applicable, (x) the date the Participant resigns with the consent of the Board, (y) the date the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (z) the date of the Effective Time (as defined in the Brookfield Merger Agreement), by (ii) 365; provided, that the Prorated Vesting Percentage shall not exceed 100%. F1 · derivative.expiration_date: On August 4, 2017, 30,000 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock. F2 · derivative.expiration_date: The 30,000 restricted stock units will vest in full on June 29, 2018. In the event that prior to June 29, 2018: (i) the Participant resigns with the consent of the Board, (ii) the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (iii) a Change in Control occurs due to a merger of the Company pursuant to the Agreement and Plan of Merger dated as of March 6, 2017 among TerraForm Global, Inc., Orion US Holdings 1 L.P. and BRE GLBL Holdings Inc. (the "Brookfield Merger Agreement") a portion of the restricted stock units equal to Prorated Vesting Percentage (as defined below) shall become fully vested. F3 · derivative.expiration_date: The "Prorated Vesting Percentage" means the percentage calculated by dividing (i) the number of days between May 25, 2017 and, as applicable, (x) the date the Participant resigns with the consent of the Board, (y) the date the Participant is removed from the Board without cause (as determined by the Board in its discretion) or (z) the date of the Effective Time (as defined in the Brookfield Merger Agreement), by (ii) 365; provided, that the Prorated Vesting Percentage shall not exceed 100%. Read SEC document |
| January 04, 2017 Filed Jan 13, 2017 22:38 UTC | TERRAFORM GLOBAL, INC. GLBL · Entity 170596 | GrantRestricted Stock Units (Class A common stock) · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001620702-17-000008 · wf-form4_148434709333117.xml · derivative · entry 1 MACK DAVID J. · CIK 0001694466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Class A Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: On January 4, 2017, 37,500 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock. F2 · derivative.exercise_price: The 37,500 restricted stock units vest on the earliest of (i) May 25, 2017, (ii) the date the Participant resigns with the consent of the Board or (iii) the date the Participant is removed from the Board without cause. Vested shares will be delivered to the reporting person as outlined in the Restricted Stock Unit Award Agreement. F1 · derivative.exercise_date: On January 4, 2017, 37,500 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock. F2 · derivative.exercise_date: The 37,500 restricted stock units vest on the earliest of (i) May 25, 2017, (ii) the date the Participant resigns with the consent of the Board or (iii) the date the Participant is removed from the Board without cause. Vested shares will be delivered to the reporting person as outlined in the Restricted Stock Unit Award Agreement. F1 · derivative.expiration_date: On January 4, 2017, 37,500 restricted stock units were awarded under the 2014 Long-Term Incentive Plan in a transaction exempt under rule 16b-3. Each restricted stock unit represents a contingent right to receive one share of TerraForm Global, Inc. Class A Common Stock. F2 · derivative.expiration_date: The 37,500 restricted stock units vest on the earliest of (i) May 25, 2017, (ii) the date the Participant resigns with the consent of the Board or (iii) the date the Participant is removed from the Board without cause. Vested shares will be delivered to the reporting person as outlined in the Restricted Stock Unit Award Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.